India rejects Novartis cancer drug patent
The Supreme Court in India has rejected an attempt by the Swiss drug maker Novartis to patent an update to a cancer treatment called Gleevec — spelled Glivec in some markets. The decision is expected to have a big impact on pharmaceutical companies and health organizations far outside the borders of India.
The BBC’s Rahul Tandon joins Marketplace Morning Report host Jeremy Hobson to discuss the global pharmaceutical market and the new patent ruling.
There’s a lot happening in the world. Through it all, Marketplace is here for you.
You rely on Marketplace to break down the world’s events and tell you how it affects you in a fact-based, approachable way. We rely on your financial support to keep making that possible.
Your donation today powers the independent journalism that you rely on. For just $5/month, you can help sustain Marketplace so we can keep reporting on the things that matter to you.
